National Cancer Institute, Research Contracts Branch, PSAS, 6120 Executive Blvd, EPS/Room 638, Bethesda, MD 20892-7227

66 -- WAVE DNA DENATURING HIGH-PERFORMANCE LIQUID CHROMATOGRAPH SYSTEM SOL RFQ90013-NS DUE 082099 POC Patricia Haun or Todd Cole, 301-402-4509 The Laboratory of Population Genetics (LPG), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute(NCI) plans to procure a WAVE DNA Denaturing High-Performance Liquid Chromatograph (DHPLC) System for fragment analysis from Transgenomic, Inc., 5600 South 42nd Street, Omaha, NE 68107. In identifying DNA sequence variations, the identification of mutations and polymorphisms is often a laborious process with most current screening techniques. It can take up to a year or longer to analyze a small number of samples for mutations in BRCA1 and BRCA 2 genes, which are involved in breast and ovarian cancer predisposition with most techniques. However, the WAVE DNA Denaturing High-Performance Liquid Chromatograph offers the relatively new technique of denaturing high performance liquid chromatography (DHPLC). This technique provides high sensitivity with rapid analysis compared to most other techniques. NCI requires the following features: 1) 90% or better of single nucleotidechanges can be detected in heterozygous human genomic DNA samples with throughput 60 or more samples per month per technician; 2) 90% sensitivity or better (as published in scientific literature) in detecting mutations, and most importantly, the conditions for sensitive analysis of both the BRCA 1 and BRCA 2 genes; 3) a "True" integrated system in that it is complete with a liquid chromatography apparatus, autosampler, oven (with a range of 35 to 80 degrees Celsius and precision of 0.1 degree Celsius), chromatography column, and software; 4) a chromatography DNASep cartridge HPLC column with a matrix formatted for the detection of sequence variation in double-stranded DNA (note this aspect is proprietary to Transgenomic); 5) the autosampler shall be formatted for 96-well trays in the laboratory, allowing injection between 1 and 100 ml of sample, and temperature controlled; and 6) the overall system shall be computer controlled. Since the WAVE DNA Denaturing High-Performance Liquid Chromatograph (DHPLC) System meets the above sensitivity and throughput requirements and there is documented evidence of successful use in identifying previously unknown mutations in both the BRCA1 and BRCA 2 genes, Transgenomic is only source known to NCI that can meet all of the above requirements. This is not a request for competitive quote. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform this requirement. Capability statements must be received in the contracting office by 3:00 p.m. EST, on August 20, 1998. If you have any questions, please contact Patricia Haun, Purchasing Agent on (301) 402-4509. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Posted 08/03/99 (W-SN362368). (0215)

Loren Data Corp. http://www.ld.com (SYN# 0392 19990805\66-0014.SOL)